Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group - Concepedia

Concepedia

Publication | Closed Access

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

249

Citations

22

References

2008

Year

David F. McDermott, Jeffrey A. Sosman, René González, F. Stephen Hodi, Gerald P. Linette, Jon Richards, James W. Jakub, Muralidhar Beeram, Stefano Tarantolo, Sanjiv S. Agarwala,

Journal of Clinical Oncology

Abstract

Sorafenib plus dacarbazine was well tolerated in patients with advanced melanoma and yielded an encouraging improvement in PFS. Based on these findings, additional studies with the combination are warranted in this patient population.

References

	Year	Citations
Mutations of the BRAF gene in human cancer Helen Davies, Graham R. Bignell, Charles Cox, Nature Somatic VariantBraf GeneGeneticsCancer GenomicsCancer Genetics	2002	10.6K
Cancer Statistics, 2007 Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward, CA A Cancer Journal for Clinicians American Cancer SocietyCancer StatisticsEpidemiologyCancer EpidemiologyHealth Policy	2007	7.5K
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Scott M. Wilhelm, Christopher Carter, LiYa Tang, Cancer Research Mutant BrafRaf/mek/erk PathwayMedicineTumor GrowthMutant Kras	2004	4K
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Mark R. Middleton, Jean‐Jacques Grob, Neil K. Aaronson, Journal of Clinical Oncology	2000	1.3K
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma Paul B. Chapman, Lawrence H. Einhorn, Michael L. Meyers, Journal of Clinical Oncology	1999	758
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Tim Eisen, T. Ahmad, Keith T. Flaherty, British Journal of Cancer	2006	633
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group Agop Y. Bedikian, Michael Millward, Hubert Pehamberger, Journal of Clinical Oncology	2006	596
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Michael B. Atkins, Lori Kunkel, Mario Sznol, PubMed	2000	516
B-RAF is a therapeutic target in melanoma Maria Karasarides, Antonio Chiloeches, Robert Hayward, Oncogene Tumor BiologyMedicineMelanomaPathologyImmune Checkpoint Inhibitor	2004	432
Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial Omar Eton, Sewa S. Legha, Agop Y. Bedikian, Journal of Clinical Oncology	2002	375

Page 1